Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
出版年份 2018 全文链接
标题
Multifaceted Role of the Urokinase-Type Plasminogen Activator (uPA) and Its Receptor (uPAR): Diagnostic, Prognostic, and Therapeutic Applications
作者
关键词
-
出版物
Frontiers in Oncology
Volume 8, Issue -, Pages -
出版商
Frontiers Media SA
发表日期
2018-02-12
DOI
10.3389/fonc.2018.00024
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Prognostic significance of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor (PAI-1) in patients with primary invasive ductal breast carcinoma – a 7.5-year follow-up study
- (2018) Sanda Jelisavac-Cosic et al. TUMORI
- SerpinB2 regulates stromal remodelling and local invasion in pancreatic cancer
- (2017) N L E Harris et al. ONCOGENE
- Prognostic and predictive biomarkers in breast cancer: Past, present and future
- (2017) Andrea Nicolini et al. SEMINARS IN CANCER BIOLOGY
- Methyl donor S-adenosylmethionine (SAM) supplementation attenuates breast cancer growth, invasion, and metastasis in vivo; therapeutic and chemopreventive applications
- (2017) Niaz Mahmood et al. Oncotarget
- uPAR directed-imaging of head-and-neck cancer
- (2017) Victor M. Baart et al. Oncotarget
- Retro-inverso Urokinase Receptor Antagonists for the Treatment of Metastatic Sarcomas
- (2017) Maria Vincenza Carriero et al. Scientific Reports
- The roles and implications of exosomes in sarcoma
- (2016) Li Min et al. CANCER AND METASTASIS REVIEWS
- Antibody-based PET of uPA/uPAR signaling with broad applicability for cancer imaging
- (2016) Dongzhi Yang et al. Oncotarget
- Urokinase-type plasminogen activator: a new target for male contraception?
- (2015) Ling Zhang et al. ASIAN JOURNAL OF ANDROLOGY
- The urokinase-type plasminogen activator (uPA) system as a biomarker and therapeutic target in human malignancies
- (2015) Shih-Chi Su et al. EXPERT OPINION ON THERAPEUTIC TARGETS
- A niche role for cancer exosomes in metastasis
- (2015) Yun Zhang et al. NATURE CELL BIOLOGY
- Progression of Osteosarcoma from a Non-Metastatic to a Metastatic Phenotype Is Causally Associated with Activation of an Autocrine and Paracrine uPA Axis
- (2015) Liliana Endo-Munoz et al. PLoS One
- PTEN expression in endothelial cells is down-regulated by uPAR to promote angiogenesis
- (2015) Matthias Unseld et al. THROMBOSIS AND HAEMOSTASIS
- Whole-exome sequencing of pancreatic cancer defines genetic diversity and therapeutic targets
- (2015) Agnieszka K. Witkiewicz et al. Nature Communications
- uPAR-targeted multimodal tracer for pre- and intraoperative imaging in cancer surgery
- (2015) Martin C. Boonstra et al. Oncotarget
- First-in-human uPAR PET: Imaging of Cancer Aggressiveness
- (2015) Morten Persson et al. Theranostics
- Urokinase receptor and resistance to targeted anticancer agents
- (2015) Steven L. Gonias et al. Frontiers in Pharmacology
- Modulation of CD44 Activity by A6-Peptide
- (2015) Malcolm Finlayson Frontiers in Immunology
- Exosomes Released from Breast Cancer Carcinomas Stimulate Cell Movement
- (2015) Dinari A. Harris et al. PLoS One
- An Anti-Urokinase Plasminogen Activator Receptor Antibody (ATN-658) Blocks Prostate Cancer Invasion, Migration, Growth, and Experimental Skeletal Metastasis In Vitro and In Vivo
- (2015) Shafaat A. Rabbani et al. NEOPLASIA
- Involvement of Urokinase-Type Plasminogen Activator System in Cancer: An Overview
- (2014) Ahmed H. Mekkawy et al. MEDICINAL RESEARCH REVIEWS
- Identification of a New Epitope in uPAR as a Target for the Cancer Therapeutic Monoclonal Antibody ATN-658, a Structural Homolog of the uPAR Binding Integrin CD11b (αM)
- (2014) Xiang Xu et al. PLoS One
- Association of Tissue mRNA and Serum Antigen Levels of Members of the Urokinase-Type Plasminogen Activator System with Clinical and Prognostic Parameters in Prostate Cancer
- (2014) Omar Al-Janabi et al. Biomed Research International
- Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients
- (2013) N. Harbeck et al. EUROPEAN JOURNAL OF CANCER
- Urokinase Plasminogen Activator System-Targeted Delivery of Nanobins as a Novel Ovarian Cancer Therapy
- (2013) Y. Zhang et al. MOLECULAR CANCER THERAPEUTICS
- Surface α-Enolase Promotes Extracellular Matrix Degradation and Tumor Metastasis and Represents a New Therapeutic Target
- (2013) Kuan-Chung Hsiao et al. PLoS One
- The Many Spaces of uPAR: Delivery of Theranostic Agents and Nanobins to Multiple Tumor Compartments through a Single Target
- (2013) Thomas V. O'Halloran et al. Theranostics
- Urokinase Plasminogen Activator Receptor (uPAR) Targeted Nuclear Imaging and Radionuclide Therapy
- (2013) Dan Li et al. Theranostics
- A Key Role for the Urokinase Plasminogen Activator (uPA) in Invasive Group A Streptococcal Infection
- (2013) Martina L. Sanderson-Smith et al. PLoS Pathogens
- The liberated domain I of urokinase plasminogen activator receptor - a new tumour marker in small cell lung cancer
- (2012) Charlotte E. Almasi et al. APMIS
- A potency of plasminogen activation system in long-term prognosis of endometrial cancer: a pilot study
- (2012) Samulak Dariusz et al. European Journal of Obstetrics & Gynecology and Reproductive Biology
- Therapeutic RNA aptamers in clinical trials
- (2012) Padma Sundaram et al. EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES
- A phase II study of a urokinase-derived peptide (A6) in the treatment of persistent or recurrent epithelial ovarian, fallopian tube, or primary peritoneal carcinoma: A Gynecologic Oncology Group study
- (2012) Michael A. Gold et al. GYNECOLOGIC ONCOLOGY
- Intracerebral infusion of the bispecific targeted toxin DTATEGF in a mouse xenograft model of a human metastatic non-small cell lung cancer
- (2012) Jun Huang et al. JOURNAL OF NEURO-ONCOLOGY
- Elevated urinary levels of urokinase-type plasminogen activator receptor (uPAR) in pancreatic ductal adenocarcinoma identify a clinically high-risk group
- (2011) Claudio Sorio et al. BMC CANCER
- Increased Plasma Soluble uPAR Level Is a Risk Marker of Respiratory Cancer in Initially Cancer-Free Individuals
- (2011) A. Langkilde et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- uPAR as Anti-Cancer Target: Evaluation of Biomarker Potential, Histological Localization, and Antibody-Based Therapy
- (2011) Ida K. Lund et al. CURRENT DRUG TARGETS
- Development of Novel Therapeutics Targeting the Urokinase Plasminogen Activator Receptor (uPAR) and Their Translation Toward the Clinic
- (2011) Andrew P. Mazar et al. CURRENT PHARMACEUTICAL DESIGN
- Cancer therapy trials employing level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
- (2011) Manfred Schmitt et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Specific knockdown of uPA/uPAR attenuates invasion in glioblastoma cells and xenografts by inhibition of cleavage and trafficking of Notch -1 receptor
- (2011) Hari Raghu et al. Molecular Cancer
- A6 Peptide Activates CD44 Adhesive Activity, Induces FAK and MEK Phosphorylation, and Inhibits the Migration and Metastasis of CD44-Expressing Cells
- (2011) R. S. Piotrowicz et al. MOLECULAR CANCER THERAPEUTICS
- uPA and uPAR shRNA inhibit angiogenesis via enhanced secretion of SVEGFR1 independent of GM-CSF but dependent on TIMP-1 in endothelial and glioblastoma cells
- (2011) Hari Raghu et al. Molecular Oncology
- Clinical significance of the plasminogen activator system in relation to grade of tumor and treatment response in colorectal carcinoma patients
- (2011) J. HALAMKOVA et al. NEOPLASMA
- Crosstalk between the urokinase-type plasminogen activator receptor and EGF receptor variant III supports survival and growth of glioblastoma cells
- (2011) J. Hu et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Vitronectin in Vascular Context: Facets of a Multitalented Matricellular Protein
- (2011) Klaus Preissner et al. SEMINARS IN THROMBOSIS AND HEMOSTASIS
- Detection of cathepsin B, cathepsin L, cystatin C, urokinase plasminogen activator and urokinase plasminogen activator receptor in the sera of lung cancer patients
- (2011) QINGYONG CHEN et al. Oncology Letters
- Nanoparticulate Alternatives for Drug Delivery
- (2010) James H. Adair et al. ACS Nano
- The predictive value of the 70-gene signature for adjuvant chemotherapy in early breast cancer
- (2010) Michael Knauer et al. BREAST CANCER RESEARCH AND TREATMENT
- Co-detection of members of the urokinase plasminogen activator system in tumour tissue and serum correlates with a poor prognosis for soft-tissue sarcoma patients
- (2010) H Taubert et al. BRITISH JOURNAL OF CANCER
- Targeting the Urokinase Plasminogen Activator Receptor Inhibits Ovarian Cancer Metastasis
- (2010) H. A. Kenny et al. CLINICAL CANCER RESEARCH
- Extracellular matrix: A gatekeeper in the transition from dormancy to metastatic growth
- (2010) Dalit Barkan et al. EUROPEAN JOURNAL OF CANCER
- Characteristics of the level-of-evidence-1 disease forecast cancer biomarkers uPA and its inhibitor PAI-1
- (2010) Karin Mengele et al. EXPERT REVIEW OF MOLECULAR DIAGNOSTICS
- Enhanced noscapine delivery using uPAR-targeted optical-MR imaging trackable nanoparticles for prostate cancer therapy
- (2010) Mohamed O. Abdalla et al. JOURNAL OF CONTROLLED RELEASE
- Soluble urokinase plasminogen activator receptor as a prognostic marker in men participating in prostate cancer screening
- (2010) A. Kjellman et al. JOURNAL OF INTERNAL MEDICINE
- Intact and cleaved forms of the urokinase receptor enhance discrimination of cancer from non-malignant conditions in patients presenting with symptoms related to colorectal cancer
- (2009) A F Lomholt et al. BRITISH JOURNAL OF CANCER
- Targeting the urokinase plasminogen activator receptor with a monoclonal antibody impairs the growth of human colorectal cancer in the liver
- (2009) George Van Buren et al. CANCER
- Receptor-Targeted Nanoparticles for In vivo Imaging of Breast Cancer
- (2009) L. Yang et al. CLINICAL CANCER RESEARCH
- The Urokinase Plasminogen Activator System: A Target for Anti-Cancer Therapy
- (2009) Salvatore Ulisse et al. CURRENT CANCER DRUG TARGETS
- Biochemical properties of plasminogen activator inhibitor-1
- (2009) Daniel Miotto Dupont Frontiers in Bioscience-Landmark
- The basics of epithelial-mesenchymal transition
- (2009) Raghu Kalluri et al. JOURNAL OF CLINICAL INVESTIGATION
- Cytokeratin 8 ectoplasmic domain binds urokinase-type plasminogen activator to breast tumor cells and modulates their adhesion, growth and invasiveness
- (2009) Nataša Obermajer et al. Molecular Cancer
- Antimetastatic Potential of PAI-1–Specific RNA Aptamers
- (2009) Charlene M. Blake et al. OLIGONUCLEOTIDES
- Components of the plasminogen activator system and their complexes in renal cell and bladder cancer: comparison between normal and matched cancerous tissues
- (2008) Paul N. Span et al. BJU INTERNATIONAL
- Tumor marker utility and prognostic relevance of cathepsin B, cathepsin L, urokinase-type plasminogen activator, plasminogen activator inhibitor type-1, CEA and CA 19-9 in colorectal cancer
- (2008) László Herszényi et al. BMC CANCER
- The Oral Serine Protease Inhibitor WX-671 – First Experience in Patients with Advanced Head and Neck Carcinoma
- (2008) Jens E. Meyer et al. Breast Care
- Assessment of Urokinase-Type Plasminogen Activator and Its Inhibitor PAI-1 in Breast Cancer Tissue: Historical Aspects and Future Prospects
- (2008) Manfred Schmitt et al. Breast Care
- Experience in Phase I Trials and an Upcoming Phase II Study with uPA Inhibitors in Metastatic Breast Cancer
- (2008) Lori J. Goldstein Breast Care
- Evolving role of uPA/uPAR system in human cancers
- (2008) Kathleen Dass et al. CANCER TREATMENT REVIEWS
- Urokinase Plasminogen Activator Receptor Choreographs Multiple Ligand Interactions: Implications for Tumor Progression and Therapy
- (2008) A. P. Mazar CLINICAL CANCER RESEARCH
- Intact and cleaved uPAR forms: diagnostic and prognostic value in cancer
- (2008) Morten et al. Frontiers in Bioscience-Landmark
- Tumor microenvironment and angiogenesis
- (2008) Pia Nyberg Frontiers in Bioscience-Landmark
- Plasminogen activator inhibitor-1 inhibits prostate tumor growth through endothelial apoptosis
- (2008) S.-C. Chen et al. MOLECULAR CANCER THERAPEUTICS
- A Peptide Accelerating the Conversion of Plasminogen Activator Inhibitor-1 to an Inactive Latent State
- (2008) L. Mathiasen et al. MOLECULAR PHARMACOLOGY
- Plasminogen activator inhibitor-1: The double-edged sword in apoptosis
- (2008) Rashna D. Balsara et al. THROMBOSIS AND HAEMOSTASIS
- Expression of urokinase-type plasminogen activator system in prostate cancer: Correlation with clinicopathological outcomes in patients undergoing radical prostatectomy
- (2008) Masafumi Kumano et al. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAdd your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload Now